Literature DB >> 15773289

Preparation, characterization, and stability of liposome-based formulations of mitoxantrone.

Sydney Ugwu1, Allen Zhang, Manjeet Parmar, Bruce Miller, Tommaso Sardone, Viktor Peikov, Imran Ahmad.   

Abstract

The preparation, characterization, and stability of lyophilized liposome-based formulation of mitoxantrone was investigated. Mitoxantrone was entrapped inside small, unilamellar liposomes composed of dioleoylphosphocholine (DOPC), cholesterol, and cardiolipin. The mean vesicle size and drug entrapment efficiency of the liposomes were approximately 150 nm and approximately 99%, respectively. Less than 1% of drug was lost and mean vesicle size remained unchanged after sterile filtration. The pre-lyophilized (pre-lyo) formulations were characterized by a differential scanning calorimetric (DSC) method. Results showed that the glass transition temperatures (Tg) increased as the molar ratios of sucrose:lipid and trehalose:lipid in the formulations were increased. The maximum Tg' of the pre-lyo formulations containing 10:1 sucrose:lipid and trehalose:lipid molar ratios were -37C and -41C, respectively. After reconstitution of the lyophilized cake of the sucrose-containing formulation, the mean vesicle size was comparable to pre-lyo liposome size. In vitro release studies showed that less than 2% of mitoxantrone was released after an extensive dialysis against phosphate buffered saline (PBS) at 37C, indicating that the mitoxantrone was highly associated and retained inside the liposomes. Short-term stability studies of the sucrose-containing formulations revealed that the reconstituted and eight-fold diluted formulations were stable for up to 8 hours at room temperature. Long-term stability studies of lyophilized liposomal mitoxantrone showed that the lyophilized formulation was stable for up to 13 months after storage at refrigerated condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15773289     DOI: 10.1081/ddc-200047850

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  7 in total

1.  Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic.

Authors:  Ebrahim Mostafavi; Atefeh Zarepour; Hamed Barabadi; Ali Zarrabi; Linh B Truong; David Medina-Cruz
Journal:  Biotechnol Rep (Amst)       Date:  2022-02-26

2.  Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes.

Authors:  Jie Zhuang; Qineng Ping; Yunmei Song; Jianping Qi; Zheng Cui
Journal:  Int J Nanomedicine       Date:  2010-08-09

3.  Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

Authors:  Yingna He; Linhua Zhang; Cunxian Song
Journal:  Int J Nanomedicine       Date:  2010-09-20

Review 4.  Cancer drug delivery in the nano era: An overview and perspectives (Review).

Authors:  Zhen Li; Shirui Tan; Shuan Li; Qiang Shen; Kunhua Wang
Journal:  Oncol Rep       Date:  2017-06-14       Impact factor: 3.906

5.  Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.

Authors:  Piotr Rychahou; Younsoo Bae; Derek Reichel; Yekaterina Y Zaytseva; Eun Y Lee; Dana Napier; Heidi L Weiss; Nick Roller; Heather Frohman; Anh-Thu Le; B Mark Evers
Journal:  J Control Release       Date:  2018-02-06       Impact factor: 9.776

6.  Study of Structural stability and formation mechanisms in DSPC and DPSM liposomes: A coarse-grained molecular dynamics simulation.

Authors:  H Hashemzadeh; H Javadi; M H Darvishi
Journal:  Sci Rep       Date:  2020-02-04       Impact factor: 4.379

Review 7.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.

Authors:  Maria Laura Immordino; Franco Dosio; Luigi Cattel
Journal:  Int J Nanomedicine       Date:  2006
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.